News | November 23, 2024
Amalgamation of Gujarat Themis Biosyn with Themis Medicare
The Scheme is subject to approval of the secured creditors and shareholders of TML and GTBL
The Scheme is subject to approval of the secured creditors and shareholders of TML and GTBL
Themis Medicare has reported total income of Rs. 123.95 crores during the period ended June 30, 2024
The company has reported total income of Rs. 107.22 crores during the period ended September 30, 2023
It ensures sufficient serum estradiol levels to alleviate menopausal symptoms
For the half year ended September 30th, 2022 revenue from operations stood at Rs. 185.44 crore in H1 FY23, as against Rs. 219.89 crore in H1 FY22, a decrease of 15.67%
Themis Medicare’s VIRALEX is an effective and safe drug for management of mild to moderate COVID and other acute viral respiratory infections.
Viralex (Inosine Pranobex) is an immunomodulatory agent with broad-spectrum antiviral properties
Viralex is an immunomodulatory agent with broad-spectrum antiviral properties. It enhances both innate & adaptive immunity and strengthens the body's defence response to viral infections
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Themis will market this drug with the brand name REMITHEM.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)